Pfizer's prostate cancer drug combination gets U.S. FDA priority review
For the combination drug, Pfizer said the FDA had set a target decision date in the last quarter of 2026
· 7/23/2026, 9:26:00 AM· 2 min read
For the combination drug, Pfizer said the FDA had set a target decision date in the last quarter of 2026
Read original story →Related stories
health
Self-medication may be temptingly easy. But it can have serious consequences
health
ICMR-NIN consortium calls for healthier school food environment, stricter regulations on marketing
health
What's the deal with peptides? The hyped market under U.S. review
health